AI

Plexium, a trailblazer in next-generation targeted protein degradation (TPD), is making waves in the oncology world with its selective monovalent degrader programs targeting SMARCA2, IKZF2, and CDK2. Showcased at the American Association for Cancer Research (AACR) Annual Meeting 2025, held from April 25–30 in Chicago, these programs highlight Plexium’s innovative approach to tackling “undruggable” cancer

OpenAI has announced that their most powerful AI model to date, GPT-4.5, will soon be discontinued for developers using their API (Application Programming Interface). This change will take effect on July 14, 2025. GPT-4.5 was only launched in late February. For developers who have been using GPT-4.5 in their applications, OpenAI recommends switching to their